4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Cerus Corporation (CERS) operates in the Medical Devices industry and is headquartered in Concord, United States with about 261 employees. Its market capitalization is roughly $615 million. In the fiscal year ended 2025-12-31, CERS reported $206M in revenue and ($16M) in net income.
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety.
Interactive charts & full statements → Open the CERS valuation workbench →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Total Revenue | $206M | $180M | $156M | $162M |
| Gross Profit | $112M | $100M | $86M | $87M |
| Operating Income (EBIT) | ($9M) | ($14M) | ($26M) | ($34M) |
| Net Income | ($16M) | ($21M) | ($38M) | ($43M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|
| Total Revenue | $54M | $58M | $53M | $52M | $43M | — |
| Gross Profit | $28M | $30M | $28M | $29M | $25M | — |
| Operating Income (EBIT) | ($0M) | ($1M) | $1M | ($3M) | ($6M) | — |
| Net Income | ($2M) | ($2M) | $0M | ($6M) | ($8M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $222M | $201M | $198M | $218M | — |
| Total Liabilities | $157M | $144M | $144M | $150M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive CERS viewer.
About TickerBase · Data methodology & sources